Burzynski Research Institute Announces Interim Cancer
Drug Results
HOUSTON--(BUSINESS WIRE) via NewsEdge
Corporation -- Burzynski Research Institute, Inc. (OTC bulletin board stock
symbol:BZYR) today announced interim results from Phase II clinical trials of
its experimental cancer drugs, Antineoplastons, in the treatment of brain
cancer.
Used in combination, Antineoplastons A10 and AS2-1 produced
responses (complete tumor elimination or greater than 50% reduction in tumor
size) in 43 of 178 evaluable patients, for a response rate of 24.1 per cent. An
additional 72 patients (40.5% of evaluable patients) experienced stable disease,
meaning their tumors did not progress, or shrink more than 50%.
The two
largest groups of patients suffered from glioblastoma multiforme (36.5%) and
astrocytoma-type tumors (32%). Approximately 10% of patients had
difficult-to-treat brain stem tumor locations.
"These results are
exciting because conventional treatments are generally considered ineffective
against primary malignant brain tumors," said Stanislaw Burzynski MD, PhD,
the firm's founder and CEO. "What makes it all the more exciting is that
these are responses in human brain cancers that are normally considered
incurable and fatal. The patients with stable disease give us hope that even the
most intractable cancers may become manageable chronic diseases."
The drugs represent a type of gene therapy that targets the signal path
of errant ras oncogenes and the p53 tumor suppressor gene. Malfunctions in these
genes are believed responsible for up to 60% of all human cancers.
"The drugs function as chemical microswitches, turning off the
signal that makes cancer cells multiply endlessly, at the same time turning on
the signal that tells the cells to undergo programmed cell death, or
apoptosis," Burzynski said. "This is an information-age approach to
cancer treatment because it uses information, rather than energy, to do the
job."
Antineoplastons were well-tolerated by most patients. The
most commonly reported adverse event was an elevated level of serum sodium. 1.3%
of all clinical trial patients had elevations of 180 mEq/L or higher at or
around the time of their deaths. Other adverse events included nausea, vomiting,
allergic skin reactions, joint and muscle pain, and fatigue, and occurred in a
small percentage of patients.
Burzynski believes the company now has
enough data to apply for FDA approval. An NDA (New Drug Application) could be
filed by the end of this year.
CONTACT: Burzynski Research Institute
Inc., Houston | Dr. Stanislaw Burzynski, 281/597-0111 | www.cancermed.com |
www.burzynskipatientgroup.org | or | Dean Mouscher, 773/404-0486
--------------------------------------------------------------------------------
I AM TRYING TO LOCATE DR STANISLAUS
BURZINSKI. CAN YOU HELP??? THANK YOU
